| GTO ID | GTC3197 |
| Trial ID | NCT05568680 |
| Disease | Malignant Mesothelioma | Ovarian Cancer | Cholangiocarcinoma |
| Altered gene | MESO |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | SynKIR-110 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma |
| Year | 2022 |
| Country | United States |
| Company sponsor | Verismo Therapeutics |
| Other ID(s) | STAR-101 |
| Cohort 1 | |||||||||
|
|||||||||